Pulse Biosciences Inc
Pulse Biosciences Inc (PLSE) is listed on NASDAQ and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Miami, United States and has 116 employees. The company is worth $3.17B. Revenue was $350K in fiscal 2025. It reported a net loss of $72.78M. The share price is 24.6% below its 52-week high of $58.90. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $17.37M. In that quarter, 2 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +118.9% over 5Y.
today you would have $2,106.69▲ +110.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $13.73 | $17.41 | $12.24 | $2.77 | $14.81 | $23.86 | $13.41 | $11.46 | $23.60 | $6.50 | |
| P/S | 311.3x | 2676.4x | — | — | 148.8x | 311.3x | — | — | — | — | — |
| P/B | 10.2x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| WRBYWarby Parker Inc. | $25.67 | 427.8x | 8.1x | 0.00% | 2.06% | $3.17B |
| CELCCelcuity Inc. | $65.57 | — | — | 0.00% | -1433.70% | $3.21B |
| ELVNEnliven Therapeutics, Inc. | $41.93 | — | 3.4x | 0.00% | -15.31% | $3.07B |
| VKTXViking Therapeutics, Inc. | $25.83 |
| 11.6x |
| 10.2x |
| 15.2x |
| — |
| 12.4x |
| 27.2x |
| 9.1x |
| 3.6x |
| 8.6x |
| 3.6x |
| EPS | -$1.08 | -$0.92 | -$0.85 | -$1.72 | -$2.28 | -$2.14 | -$2.26 | -$2.20 | -$1.73 | -$0.86 |
| Profit margin | -8357.86% | -20794.57% | — | — | -8357.86% | -4489.42% | — | — | — | — | — |
| ROE | -90.24% | -90.24% | -46.65% | -95.15% | — | -178.37% | -217.75% | -152.82% | -56.60% | -55.59% | -37.62% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 7.4x |
| 0.00% |
| -88.85% |
| $3.28B |
| ATRCAtriCure, Inc. | $59.30 | 282.4x | 5.8x | 0.00% | 2.15% | $3.02B |
| DNLIDenali Therapeutics Inc. | $18.66 | — | 3.6x | 0.00% | -54.93% | $2.98B |